Amylyx’s ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug
Relyvrio, Amylyx’s FDA-approved ALS drug, has failed a crucial Phase III trial, the company said on Friday, a major blow to what had been considered one of the few…